The predictive value of immune inflammation indexes for the risk of fracture in patients with osteoporosis: a systematic review and meta-analysis

Yawei Xu, Xiaoming He, Xu Zhang, Shilong Meng, Chengjie Wang, Yifeng Yuan, Xiaolin Shi, Kang LiuFrontiers in Endocrinology 2025 · DOI

Abstract: PROSPERO, identifier CRD420251053366.

Introduction: The Challenge of Predicting Fragility Fractures

Osteoporosis is a major global health concern, characterized by decreased bone mass and microarchitectural deterioration, leading to an increased risk of fragility fractures. While tools like Bone Mineral Density (BMD) and the Fracture Risk Assessment Tool (FRAX) are clinical standards, they often fail to capture the dynamic biological processes driving bone loss. Specifically, the concept of "immunoporosis"—the interplay between the immune system and bone metabolism—has emerged as a critical factor. Pro-inflammatory states can stimulate osteoclast activity, accelerating bone resorption. This study aims to evaluate whether simple, cost-effective immune-inflammation markers derived from routine blood tests can serve as reliable predictors of fracture risk.

Methods: Systematic Review and Meta-Analysis

Following PRISMA 2020 guidelines, a comprehensive search was conducted across databases including PubMed, Embase, Cochrane Library, Web of Science, Wanfang, and CNKI for studies published up to March 2025. The review focused on five key indexes:

  • NLR: Neutrophil-to-lymphocyte ratio
  • SII: Systemic immune-inflammation index (Platelets × Neutrophils / Lymphocytes)
  • LMR: Lymphocyte-to-monocyte ratio
  • PLR: Platelet-to-lymphocyte ratio
  • SIRI: Systemic inflammation response index (Neutrophils × Monocytes / Lymphocytes)
Figure 1: Literature retrieval and study selection process according to PRISMA guidelines.

The final analysis included eight studies (four cohort and four case-control) involving 3,769 participants, primarily from East Asia. Statistical analysis was performed using STATA 18.0 and Review Manager 5.4, utilizing random-effects models to calculate pooled Odds Ratios (OR) and Standardized Mean Differences (SMD) to account for study heterogeneity.

Results: The Role of "Immunoporosis" in Fracture Risk

The meta-analysis confirmed that several immune-inflammation indexes are significantly associated with fracture risk in osteoporotic patients. The findings reinforce the theory that bone health is inextricably linked to the immune system. High levels of neutrophils (pro-inflammatory) and low levels of lymphocytes (often anti-inflammatory in this context) create a "perfect storm" for bone resorption.

Key quantitative findings include:

  • NLR as the Strongest Predictor: Patients with high NLR had a 73% higher risk of fracture (OR = 1.73, 95% CI: 1.40–2.14). This was the most robust association found across various subgroups.
  • LMR as a Protective Marker: Conversely, a higher LMR appeared protective, associated with a 15% reduction in fracture risk (OR = 0.85, 95% CI: 0.77–0.93).
  • SII and Continuous Analysis: The Systemic Immune-Inflammation Index showed a significant but modest link (OR = 1.01). When treated as continuous variables, NLR, LMR, SII, PLR, and SIRI all showed significant differences between fracture and non-fracture groups.

Subgroup analysis revealed that these markers might be more sensitive in younger populations (under 65) compared to older individuals. This is likely due to "immunosenescence"—the natural decline of the immune system with age which can dampen inflammatory signals, making them less distinct in the elderly.

Discussion: Clinical Implications and Future Directions

These findings underscore the clinical potential of using routine hematological parameters to refine fracture risk assessment. Unlike BMD, which provides a static snapshot of bone structure, these indexes reflect the active inflammatory environment contributing to bone decay. Because these indexes are calculated from a standard Complete Blood Count (CBC), they offer a low-cost, accessible method to improve the accuracy of existing clinical risk assessment models like FRAX.

However, several hurdles must be cleared before these markers become standard clinical practice. The geographic concentration of studies in East Asia (predominantly China and South Korea) limits the generalizability of the results to Caucasian or African populations. Furthermore, the retrospective nature of many included studies introduces potential selection bias.

Future research should focus on large-scale, prospective longitudinal trials across diverse populations to establish standardized clinical cut-off values. Integrating these biological markers into a "composite predictive model" that combines biological data with traditional structural data (like BMD) could lead to more personalized and accurate fracture prevention strategies.

Summary updated

Abstract

PROSPERO, identifier CRD420251053366.
BibTeX
@inproceedings{xu2025predictive,
  author = {Yawei Xu and Xiaoming He and Xu Zhang and Shilong Meng and Chengjie Wang and Yifeng Yuan and Xiaolin Shi and Kang Liu},
  title = {{The predictive value of immune inflammation indexes for the risk of fracture in patients with osteoporosis: a systematic review and meta-analysis}},
  booktitle = {Frontiers in Endocrinology},
  year = {2025},
  doi = {10.3389/fendo.2025.1650895},
}
Figure